MetLife, Inc. (MET), headquartered in New York City, is a leading global provider of insurance, annuities, and employee benefit programs, serving millions of customers across more than 40 countries. With a market cap of $59 billion, MetLife is at the forefront of delivering innovative financial solutions, empowering individuals, families, and businesses to achieve financial security while maintaining a strong commitment to customer service, corporate responsibility, and long-term sustainability.
Companies with a market value of $10 billion or more are classified as “large-cap stocks,” MetLife is solidly within this category. This classification underscores its substantial size, global reach, and leadership in the financial services sector. MetLife provides a comprehensive suite of insurance, annuity, and employee benefit solutions, showcasing its commitment to financial security, customer-centric innovation, and sustainable practices to meet the diverse needs of its customers worldwide.
MetLife shares are trading 7.6% below their 52-week high of $89.05, which they hit on Nov. 27. The stock has gained 9% over the past three months, outperforming the SPDR S&P Insurance ETF (KIE), which has gained 6.8% over the same time frame.
However, over the longer term, MET has rallied 24.4% on a YTD basis, trailing KIE's stronger performance of 31.1% returns. Similarly, over the last 52 weeks, MET's 28.4% increase falls short of KIE's 31.5% rise.
MET has remained above its 200-day moving average since early August, reflecting a positive long-term outlook. However, the recent drop below its 50-day moving average signals a bearish short-term trend.
MetLife has recently demonstrated strength in its core businesses, including insurance and retirement solutions, driven by robust growth, effective cost-cutting measures, and strategic investments. However, the stock faced a 5.7% decline following its Q3 earnings report on Oct. 30. The company posted adjusted EPS of $1.93, down 1% year over year and below the consensus estimate of $2.16. Revenue rose by 16.2% to $18.44 billion but narrowly missed expectations.
MetLife’s competitor, Aflac Incorporated (AFL), has outperformed MET, delivering a YTD return of 27.3%.
Analysts maintain an optimistic outlook for MET, as the stock has recently outperformed the broader sector. MET has a consensus “Strong Buy” rating overall from the 16 analysts covering the stock and has a mean price target of $93.50, suggesting a potential upside of 13.6% from its current price.
On the date of publication, Rashmi Kumari did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. More news from Barchart- This Penny Stock Just Surged 380% on a Mega Deal. Is It a Buy, Sell, or Hold?
- Can This AI Penny Stock Rise 184% in 2025?
- Chinese Stocks Are Getting a Major Economic Boost. Is It Time to Buy NIO Stock?
- 2 Tech Stocks That Could Start Paying Dividends in 2025
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
